Calendario›MDWD›DGD
DGD
Enzymatic Debridement in Burns Patients: A Comparison to Standard of Care
Ensayo de MediWound Ltd. en Quemadura.
- Fase
- Fase 3
- Estado
- Completado
- Participantes
- 182
- Centros
- 17
- Fin del objetivo primario
- oct 2009
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, abierto. Comenzó en dic 2005.
Qué mide
Co-primario: % de heridas tratadas escindidas (por excision tangencial/menor/Versajet) o dermoabrasion, en la primera cirugia, de heridas de espesor parcial profundo (Surgical excision/dermabrasion performed as initial debridement (surgical SOC group) or as first post-debridement procedure (DGD or non-surgical SOC groups)) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroBurns represent one of the most severe and dreaded traumas. Burned and traumatized tissue is known as eschar. The dead eschar, if not removed, often becomes heavily contaminated and is the source of local and/or systemic infection or sepsis. The local inflammation and infection destroy healthy surrounding tissues and extends the original damage. In order to prevent these complications, and in order to minimize the risk of infection, it is imperative to evaluate the burn and remove all of the offending eschar at the earliest possible opportunity. This removal of dead tissue is termed "debridement". The most direct debridement method for eschar removal is surgery. Traditional, conservative non-surgical debridement is a lengthy process which often involves many complications. The objective of this study is to evaluate the safety and enzymatic debriding efficacy of Debrase Gel Dressing (DGD) in hospitalized patients with deep partial thickness and/or full thickness thermal burns and to compare DGD to standard of care (SOC).
Más ensayos de MDWD
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| EscharEx 5% | Fase 1/2 | Reclutando pacientes | may 2022 (prevista, ya pasada: sin actualizar en el registro) |
| EscharEx · VALUE | Fase 3 | Reclutando pacientes | dic 2026 (prevista) |
| EscharEx · VLU | Fase 2 | Aún sin reclutar | dic 2027 (prevista) |
| EX-03 | Fase 2 | Aún sin reclutar | ago 2028 (prevista) |
| EscharEx | Fase 2 | Completado | may 2022 (real) |
| EscharEx | Fase 2 | Completado | dic 2021 (real) |
Todos los de MDWD, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT00324311), actualizada en may 2011.